Medpace Holdings, Inc. (NASDAQ:MEDP) Position Lessened by Swiss National Bank

Swiss National Bank lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 10.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,200 shares of the company's stock after selling 5,500 shares during the quarter. Swiss National Bank owned 0.16% of Medpace worth $14,775,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Medpace by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company's stock worth $102,013,000 after buying an additional 319,210 shares during the last quarter. Invesco Ltd. raised its position in shares of Medpace by 67.6% during the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company's stock worth $148,159,000 after purchasing an additional 246,775 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Medpace in the 3rd quarter valued at approximately $30,252,000. International Assets Investment Management LLC lifted its stake in Medpace by 248,773.8% in the 4th quarter. International Assets Investment Management LLC now owns 104,527 shares of the company's stock valued at $32,041,000 after buying an additional 104,485 shares in the last quarter. Finally, Lord Abbett & CO. LLC grew its holdings in Medpace by 682.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 114,588 shares of the company's stock valued at $27,745,000 after buying an additional 99,949 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $9.01 during trading on Friday, reaching $390.19. 251,470 shares of the stock were exchanged, compared to its average volume of 269,637. The firm's 50-day moving average price is $397.45 and its 200 day moving average price is $336.60. The firm has a market cap of $12.09 billion, a price-to-earnings ratio of 39.77, a price-to-earnings-growth ratio of 1.99 and a beta of 1.40. Medpace Holdings, Inc. has a 12-month low of $197.39 and a 12-month high of $421.00.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same quarter in the prior year, the business earned $2.27 earnings per share. The business's quarterly revenue was up 17.7% compared to the same quarter last year. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of analyst reports. StockNews.com raised Medpace from a "hold" rating to a "buy" rating in a research note on Tuesday, April 23rd. Guggenheim lifted their price target on shares of Medpace from $453.00 to $464.00 and gave the stock a "buy" rating in a report on Wednesday, April 24th. Robert W. Baird raised their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 24th. UBS Group raised Medpace from a "neutral" rating to a "buy" rating and increased their price target for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Finally, Jefferies Financial Group raised Medpace from a "hold" rating to a "buy" rating and lifted their price objective for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Medpace has an average rating of "Moderate Buy" and an average price target of $443.00.

Insider Activity at Medpace

In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the sale, the insider now owns 5,539,947 shares of the company's stock, valued at $2,170,274,237.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares of the company's stock, valued at $2,170,274,237.25. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 100,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares of the company's stock, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 209,224 shares of company stock worth $84,618,441. 20.30% of the stock is currently owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.